Dr.

Gang Liu, Ph. D.

**** ******* *** #**, *** Diego, CA 92122

Tel: 858-***-**** E-mail: *******@*****.***

Objective

• To apply for a Senior Scientist position in Process chemistry.

Summary of Qualifications and Skills

• Proven track record in design and synthesis of bioactive compounds and total synthesis of complex natural products.

• Proven track record in chemical process development and optimization and scale up to kilogram. Strong experience in providing novel and creative solutions to process development problems.

• Excellent skills in modern organic synthesis (tradition, solid phase, parallel and microwave) and purification (FCC, PLC, ISCO, HPLC, crystallization, et al) techniques and broad knowledge of organic/medicinal chemistry.

• Strong problem-solving skills; highly motivated independent productive team player.

• Excellent skills: NMR, MS, LCMS, IR, LC, TLC, HPLC, ChemOffice, Scifinder etc.

Professional Experiences

• 2008-present: Research Scientist. Medicinal chemistry, CytRx Co. San Diego, CA.

Designing and synthesizing small molecular chaperone which aims to repair or degrade misfolded proteins associated with disease such as neurodegenerative disease and cancers. Working at beach with multi-reactions (2-3) routinely, presentation biweekly.

♦ Designed, synthesized, purified and characterized 92 novel final compounds (4-9 step syntheses) independently for biological assays. Obtained outstanding achievement award for the high productivity at CytRx 2008.

♦ Discovered the novel lead active compounds (EC50 0.06-1 µM) with therapeutic index>100. Two of them were scaled up and in PK study.

♦ Interacted with a multidisciplinary team of medicinal chemists, biologists, pharmacologists and SAR in drug design. Five papers with one published, one submitted and revised, one submitted and two to be submitted. One patent application filed.

• 2004-2008: Senior Scientist. Organic/Medicinal chemistry; Acme Bioscience Inc., Palo Alto, CA. Synthesized, Scaled up and optimized Active Pharmaceutical Ingredients (APIs) and Novel heterocyclic compounds efficiently and independently. Developed novel and creative solutions to overcome synthetic and process problems. Worked at bench with multiple projects to adapt rapidly to new projects, fast paced environment with rapidly evolving timelines and targets.

♦ Designed and synthesized 5 complex APIs with chiral centers (highest challenge, 15 to 26 steps with asymmetrical synthesis). Discovered and well developed the synthetic routes and Scaled up with novel and creative solution up to final amount of 50g.

♦ Designed and synthesized lots of APIs (heterocyclic compounds) containing O, N, S, B, P (multi-steps. 4-12 steps) including oligonucleotides. Scaled up to kilograms.

♦ Synthesized APIs and optimized the synthetic process by novel solution to finally every step just simple work up without column purification and the final products obtained by crystallization (purity>95%, hundreds of grams).

• 2003-2004: Scientist. Synthetic organic chemistry. SynPep Co. Dublin, CA.

Performed peptide synthesis, coupling, cleavage and identification, Amino acid modification, peptide modifications such as introduction of dye, peptide reduction, oxidation, preparation of CMK and epoxide, etc. Supervised cleavage group and developed cleavage cocktails.

• 2002-2003: Postdoctoral Associate, medicinal chemistry; cancer center, the Burnham Institute for Medical Research, La Jolla, CA. Advisor: Prof. Marcia Dawson.

Designed and synthesized active molecules for anticancer research and drug discovery.

♦ Structure-base drug discovery and SAR in drug design.

♦ Designed and Executed multi-step (5-18 steps) syntheses of novel active molecules containing heterocycles (such as Pyridine, pyrimidine, tetrazole, thioazolidine, et al).

♦ Discovered active compounds against cancer. Three papers published in J. Med. Chem. and one in Cancer Research.

• 1999-2002: Postdoctoral Associate, synthetic organic chemistry; Texas Christian University, Fort Worth, TX. Advisor: Prof. David Gutsche (Robert Welch professor).

Designed and synthesized 8 new high functinalized calix[6]arenes (10-15 steps syntheses) for aldolase mimics.

• 1996-1999: Ph. D. student, synthetic organic chemistry; Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences. Advisor: Prof. Zhiqin Wang,

First total syntheses of complex natural products-koninginins (Koninginins, with 3 to 6 chiral centers, were isolated from metabolite and identified by spectra).

♦ Designed and synthesized Koninginin D, E, B and F (20-22 steps, 3-4 chiral centers)

♦ Determined absolute configuration Koninginin D & E.

♦ Corrected the structure of Koninginin B & F.

♦ Discovered a new route to 5-isoxazolamines.

Education

Ph. D. (09/1996 to 06/1999), organic chemistry. Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Sciences, Shanghai, China; Dissertation: “First Total synthesis of Koninginin B, D, E, F’; Advisor: Prof. Zhiqin Wang (former president of SIOC)

Selected Publications

1. Liu G, Murali Mohan Reddy PS, Barber JR, Ng SC, Zhou Y. “Synthesis of Novel 3,7-dihydro-purine-2,6-dione Derivatives”. Synthetic Communication. 2009, Accepted and in press.

2. Zhou Y, Vu K, Chen Y, Pham J, Brady T, Liu G, Chen J, Nam J, Murali Mohan Reddy PS, Au Q, Yoon IS, Tremblay MH, Yip G, Cher C, Zhang B, Barber JR, Ng SC.“Chloro-oxime Derivatives as Novel Small Molecule Chaperone Amplifiers”. Bioorg Med Chem Lett. 2009, 19, 3128-3135.

3. Zhou Y, Brady T, Liu G, Chen J, Nam J, Murali Mohan Reddy PS, Au Q, Yoon IS, Tremblay MH, Yip G, Cher C, Zhang B, Barber JR, Ng SC.“Pyrimido[5,4-e][1,2,4]triazine-5,7(1H, 6H)-dione Derivatives as Novel Small Molecule Chaperone Amplifiers”. Bioorg Med Chem Lett. 2009, submitted.

4. Patent application: Zhou Y, Liu G, Chen J, Brady T, Murali Mohan Reddy PS, Barber JR, Ng SC “HSF1 activitors” April 2009 filed.

5. Dawson M, Liu G, et al. “An Adamantyl-Substituted Retinoid-Derived Molecule That Inhibits Cancer Cell Growth and Angiogenesis by Inducing Apoptosis and Binds to Small Heterodimer Partner Nuclear Receptor: Effects of Modifying Its Carboxylate Group on Apoptosis, Proliferation, and Protein-Tyrosine Phosphatase Activity”. J Med Chem. 2007, 50(11); 2622 – 2639.

6. Dawson M, Liu G, et al. “Adamantyl-substituted Retinoid-related Molecules Bind Small Heterodimer Partner and Modulate the Sin3A”. Cancer Research. 2007 67(1):318-25.

7. Dawson M, Liu G, et al. “Antagonist Analogue of 6-[3’-(1-Adamantyl)-4’-Hydroxyphenyl]-2-Naphthalenecarboxylic Acid (AHPN) Family of Apoptosis Inducers that Effectively Block AHPN-Induced Apotosis but not Cell-Cycle Arrest”. J. Med. Chem. 2004, 47, 3518-3536.

8. Liu G, Dawson M, et al. “Determinants of Retinoid X Receptor Transcriptional Antagonism”. J. Med. Chem. 2004, 47, 4360-4372.

9. Conference presentation: Dawson M, Liu G, “Effects of Breast Cancer Apoptosis-Inducing Agents on Blood Vessel Cells” California Breast Cancer Research Program Symposium (A Decade of Progress), San Diego, CA. Sept. 12-14, 2003.

10. Dawson M., et al. “Induction of apoptosis in cancer cells.” Publ.:US2003/176506 (2003). (I made contribution to the patent).

11. Liu G, Wang Z. “Total Synthesis of Koninginin B, D, and E” Synthesis 2001, 119.

12. Liu G, Wang Z.. “First Total Synthesis of (+)-Koninginin D” Chem. Commun. 1999, (12), 1129

13. Liu G, Wang Z. “A New Synthetic Route to 5-Isoxazolamines” Chinese Chemical Letters 1999, 10(8), 647.

14. Liu G, Wu C.. “Studies on Synthesis of Biphenyl 33- and 22-Membered Ring Crown Ether Containing Pyridine and Central Functional Group” HECHENG HUAXUE (Chinese J. Synthetic Chemistry) 1996, 4(3), 251. CA* 126, 171576.

15. Liu G, Wu C. “Studies on Synthesis of New Biphenyl 11,14 and 17-Membered Ring Pivot Lariat Crown Ether” YOUJI HUAXUE (Chinese J. Organic Chemistry) 1996, 23. CA* 124,343252.

Reference

• Available upon request

PS: I am US Permanent Resident (Green Card holder). I am authorized to work in the US and I am available immediately.

Contact this candidate